Ziagen

Ziagen is a brand name of abacavir, approved by the FDA in the following formulation(s):

ZIAGEN (abacavir sulfate - solution; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: December 17, 1998
  
  Strength(s): EQ 20MG BASE/ML ^[RLD]

ZIAGEN (abacavir sulfate - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: December 17, 1998
  
  Strength(s): EQ 300MG BASE ^[RLD]

Has a generic version of Ziagen been approved?

No. There is currently no therapeutically equivalent version of Ziagen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ziagen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Therapeutic nucleosides
  Patent 5,034,394
  Issued: July 23, 1991
  Inventor(s): Daluge; Susan M.
  Assignee(s): Burroughs Wellcome Co.
  The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.
  
  Patent expiration dates:
  
  
  • December 18, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 18, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Carbocyclic nucleoside hemisulfate and its use in treating viral infections
  Patent 6,294,540
  Issued: September 25, 2001
  Inventor(s): Brodie; Alastair Couper & Jones; Martin Francis & Seager; John Frederick & Wallis; Christopher John
  Assignee(s): Glaxo Wellcome Inc.
  The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene- 1-methanol or a solvate of it is used in the treatment of viral infections.
  
  Patent expiration dates:
  
  
  • May 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 14, 2018
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions
  Patent 6,641,843
  Issued: November 4, 2003
  Inventor(s): Nikki Thoennes; Brooks
  Assignee(s): SmithKline Beecham Corporation
  The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89).
  
  Patent expiration dates:
  
  
  • February 4, 2019
    
    ✓ 
    Drug product
  
  
  
  • August 4, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Ziagen Consumer Information (Wolters Kluwer)
• Ziagen Solution Consumer Information (Wolters Kluwer)
• Ziagen Consumer Information (Cerner Multum)
• Ziagen Advanced Consumer Information (Micromedex)
• Ziagen AHFS DI Monographs (ASHP)
• Abacavir Consumer Information (Wolters Kluwer)
• Abacavir Solution Consumer Information (Wolters Kluwer)
• Abacavir Consumer Information (Cerner Multum)
• Abacavir Advanced Consumer Information (Micromedex)
• Abacavir Sulfate AHFS DI Monographs (ASHP)